Immutep Ltd ( (AU:IMM) ) has provided an announcement.
Immutep Ltd announced a change in the director’s interest, with Mr. Marc Voigt acquiring 2,400,000 fully paid ordinary shares through the vesting and exercising of performance rights. This transaction, approved by shareholders at the 2021 AGM, reflects the company’s ongoing commitment to aligning executive interests with shareholder value, potentially impacting investor confidence and market perception.
More about Immutep Ltd
Immutep Ltd is a biotechnology company focused on developing immunotherapy treatments for cancer and autoimmune diseases. The company specializes in products that modulate the immune system, with a particular emphasis on leveraging LAG-3, a protein involved in immune regulation, to enhance immune responses against diseases.
YTD Price Performance: -9.09%
Average Trading Volume: 5,000
Technical Sentiment Signal: Strong Buy
Current Market Cap: $224M
Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.